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Abstract: Protective immunity against anthrax is inferred from measurement of vaccine 
antigen-specific neutralizing antibody titers in serum samples. In animal models, in vivo 
challenges with toxin and/or spores can also be performed. However, neither of these 
approaches considers toxin-induced damage to specific organ systems. It is therefore 
important to determine to what extent anthrax vaccines and existing or candidate adjuvants 
can provide organ-specific protection against intoxication. We therefore compared the 
ability of Alum, CpG DNA and the CD1d ligand α-galactosylceramide (αGC) to enhance 
protective antigen-specific antibody titers, to protect mice against challenge with lethal 
toxin, and to block cardiotoxicity and hepatotoxicity. By measurement of serum cardiac 
Troponin I (cTnI), and hepatic alanine aminotransferase (ALT), and aspartate aminotransferase 
(AST), it was apparent that neither vaccine modality prevented hepatic intoxication, despite 
high Ab titers and ultimate survival of the subject. In contrast, cardiotoxicity was greatly 
diminished by prior immunization. This shows that a vaccine that confers survival following 
toxin exposure may still have an associated morbidity. We propose that organ-specific 
intoxication should be monitored routinely during research into new vaccine modalities. 
OPEN ACCESS
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1. Introduction 
Bacillus anthracis secretes an 83 kDa protein, known as protective Ag (PA), that forms heptameric 
pores on the surface of target cells expressing anthrax toxin receptors (capillary morphogenesis  
protein-2, CMG-2 and tumor endothelial marker-8,TEM-8) [1,2]. PA heptamers interact with lethal 
factor (LF) and edema factor (EF) to form lethal toxin (LT) and edema toxin (ET), respectively, which 
together are known as anthrax toxin [2]. The PA heptamer facilitates entry of EF and LF into the target 
cell. Within the target cell LF functions as a zinc-dependent metalloprotease and cleaves mitogen 
activated protein kinase kinases [3]. Following cell entry, EF, which has calmodulin-dependent 
adenylate cyclase activity, generates high concentrations of cAMP [4]. LT and ET have potent  
immune-subversive effects during the early stages of infection, inhibiting the functions of dendritic cells, 
B cells, T cells and NKT cells [5–8]. In later stages of infection, anthrax toxin is lethal in animal models 
and causes a broad range of defects in target cells, including altered cell cycle, cell growth and survival [9]. 
A recent study using organ-specific conditional knockout of the TEM-8 and CMG-2 receptors, 
demonstrated that LF largely asserts its lethality on the heart, despite intoxication of multiple organ  
systems [10]. In contrast, EF largely causes lethality via the liver and gastrointestinal system [10]. 
Collectively the activities of anthrax toxin cripple the host and allow B. anthracis to grow to high 
numbers in the bloodstream [2,5–8,10]. Hence, immune neutralization of PA counters the damaging 
effects of anthrax toxin, providing protection to the host during early stages of disease. PA-specific Ab 
neutralizes anthrax toxin in vitro and protects immunized animals in vivo following a lethal  
challenge [11–16]. There is a strong correlation between PA-specific Ab titers and toxin neutralization 
by sera from patients who have survived B. anthracis infection [17]. Consequently, there is considerable 
interest in development of vaccines, which incorporate PA as the immunogen [17,18]. The current 
vaccine anthrax vaccine-adsorbed (AVA) administered to US military personnel consists of PA and 
induces PA-specific Ab titers sufficient to neutralize anthrax toxin [17,18]. However, what is not  
well-appreciated is the extent to which PA-specific Ab protects the cardiac and the hepatic systems from 
intoxication. In light of the new studies showing that LF mediates lethality via the heart [10], it is 
important to evaluate the effects of immunization on intoxication. 
Herein, we show that immunization of mice with PA induced Ab titers that were protective against 
cardiotoxicity and lethality following in vivo challenge with LT. However, anti-PA Abs did not protect 
against hepatotoxicity. This pattern was also observed when different types of adjuvant were included 
in the PA vaccine. This work suggests that anthrax vaccination might protect the host from lethality,  
but not from all sources of organ damage and associated morbidity. 
  




2.1. Anthrax Toxin Leads to Elevation of Serum Hepatic AST and ALT and Cardiac Troponin I in 
Naïve Mice 
Following an i.v. challenge of naïve C57Bl/6 mice with LT, a clear elevation in serum concentrations 
of hepatic AST and ALT, as well as cardiac Troponin I (cTN1) was observed (Figure 1A). Mice treated 
with LT ultimately succumbed to intoxication and had 0% survival 5 days after toxin administration 
(Figure 1B). Elevation of serum concentrations of AST, ALT and cTn1 was dose-dependent with respect 
to LT (Figure 1C). Intoxication was most evident 48 hours after treatment with LT but could be observed 
after 24 hours (Figure 1D). Intoxication and lethality of LT required both the PA protein and 
enzymatically-active LF. Administration of either protein alone, or PA combined with an inactive LT 
mutant failed to cause elevation of AST, ALT, cTn1 (Figure 1E) or result in death (Figure 1F).  
These results demonstrate that LT administration led to hepatotoxicity, as well as cardiotoxicity. 
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Figure 1. Anthrax toxin leads to elevation of serum hepatic AST and ALT and cardiac 
Troponin I in naïve mice. (A) C57Bl/6 mice were treated with LT in PBS or PBS alone and 
blood samples collected after 48 h. AST, ALT and Troponin I concentrations were then 
measured. Data show the mean ± SEM enzyme concentration (n = 10 per group);  
(B) Mice were treated with either LT in PBS or PBS alone. Mice were observed for times 
indicated and survival monitored (n = 10 per group); (C) Mice were treated with the doses 
of LT indicated and rested for 48 h before collecting blood samples and measuring AST, 
ALT and cTnI. Each data point represents an individual mouse; (D) Mice were treated with 
LT and blood samples were collected at times shown. Data shows the mean ± SEM serum 
AST, ALT and cTnI enzyme concentrations (n = 3 per group); (E) Mice were treated with 
PA, LF, mutant lethal factor (mLF), mLT or LT and blood samples were collected at 48 h. 
AST, ALT and cTnI were then measured. (F) Survival was monitored (n = 5 per group). 
Statistical significance in (A) and (D) were determined by Mann Whitney U-test, and in (E) 
by one-way ANOVA and Bonferroni’s multiple comparisons post-test. Statistical 
significance in (B) and (F) was determined by performing Kaplan-Meier analysis in 
conjunction with a log rank test. The p values indicate significant differences between 
survival of the PBS- and the LT-treated groups in (B), and between all groups and the  
LT-treated group in (F). 
2.2. Immunization with PA Induces Ab and Inhibits Cardiotoxicity but not Hepatotoxicity 
Following immunization of mice with PA, anti-PA IgG1, IgG2b and IgG2c titers were readily 
detected in the serum (Figure 2A). This is consistent with numerous published reports [12,16,19–21]. 
When naïve and PA-immunized mice were challenged i.v. with LT, significant AST elevations were 
observed in naïve and immunized mice, albeit of a lesser magnitude in the immunized group  
(Figure 2B). There was no statistical difference in the elevations of serum ALT in naïve and immunized 
groups. Additionally, elevations in cTn1 were effectively blocked in all mice in the PA-immunized group 
(Figure 2B). Closer examination of hepatotoxicity revealed a modest but significant decline in 
coagulative necrosis in the PA-immunized mice (Figure 2C,D). However, an increase in leukocyte 
infiltration was evident in LT-challenged PA-immunized mice as compared to other groups (Figure 2D). 
These data show that immunization of mice with PA resulted in an Ab response that blocked the 
cardiotoxicity but had only minor effects on the hepatotoxicity associated with LT. 





Figure 2. Immunization with PA induces PA-specific Ab and inhibits cardio- but not  
hepato-toxicity. (A) C57Bl/6 mice were immunized with 8 µg of PA in PBS on day 0 and 
boosted with 5 µg of PA on day 28. Mice were bled on days indicated. Data show  
PA-specific IgG1 (left), IgG2b (center) and IgG2c (right) Ab titers. Each data point 
represents an individual mouse; (B) Naïve and PA-immunized mice were treated with LT 
and blood samples collected after 48 h. AST, ALT and Troponin I were then measured. Data 
show the mean ±SEM serum enzyme concentrations (n = 5 for naïve group, n = 10 for 
immunized group). Two outliers (non-responders with value = 0) were removed from the 
naïve challenged group in the cTn1 assay; (C) Liver sections were prepared from parallel 
groups of mice and stained with H&E; (D) Slides were scored for leukocyte infiltration and 
coagulative necrosis (n = 5 per group). Statistical significance in (A,B) and (D) was 
determined by one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
Toxins 2015, 7 2376 
 
 
2.3. Inclusion of Adjuvants in the PA Vaccine Does not Affect LT-Induced Hepatotoxicity  
Anti-PA titers were compared when PA was administered alone, adsorbed to Alum adjuvant, or mixed 
with αGC or CpG DNA (Figure 3A,B). Although PA alone was immunogenic, IgG1 titers were modestly 
increased by inclusion of adjuvants (Figure 3A). Ab responses were dominated by IgG1, except in the 
case of CpG DNA which induces a Th1-polarized response, consistent with the higher IgG2b and IgG2c 
titers observed (Figure 3B). 
Immunized mice and additional naïve controls were challenged with LT before collecting blood 
samples, measuring AST, ALT (Figure 3C) and cTn1 (Figure 3D). Neither of the adjuvants used affected 
LT-induced elevations in serum AST or ALT. As observed in the previous experiment, immunization 
with PA alone reduced elevation of serum cTn1. The inclusion of adjuvants led to a variable cTn1 
response in those experimental groups, which was not significantly different from controls. It should be 
noted that some mice succumbed to toxin before collecting serum samples. 
Survival was monitored and as expected, all naïve mice succumbed to LT within 4 days (Figure 3D). 
There was a 40% survival rate in the PA-immunized mice, an 80% survival rate in the CpG-immunized 
mice, and a 100% survival rate in the Alum- or α-GC-immunized mice (Figure 3E). 
These data show that the vaccine adjuvants tested did not enhance Ab responses in a manner that 
increased protection against LT-induced cardiotoxicity or hepatotoxicity as compared to immunization 
with PA alone. However, inclusion of adjuvants did improve overall survival, thus delineating morbidity 
and lethality. 
 
Figure 3. Cont. 





Figure 3. Effects of adjuvant inclusion on PA-specific Ab titers and LT-induced toxicity. 
Mice were immunized and bled according to schedule in Figure 2 using the formulations 
indicated (A) Shows PA-specific IgG1 titers; (B) Shows PA-specific IgG2b and IgG2c titers. 
9–10 mice per group were immunized. Naïve and immunized mice were bled and then 
treated with high dose LT split over two doses (200 µg PA plus LF followed by 100 µg PA 
plus LF 24 h later). Statistical significance in (A) and (B) was determined by one-way 
ANOVA and Bonferroni’s multiple comparisons post-test; (C) ALT and AST were 
measured as described (n = 3–5 mice per group). One-way ANOVA did not reveal 
significant differences between groups in (C). The p value shown in (C) results from Mann-
Whitney U test comparison of the naïve/unchallenged and naïve/LT-challenged groups;  
(D) Troponin I concentrations were then measured as described (n = 3–5 mice per group). 
One way ANOVA revealed significant differences between the means and p value ranges 
indicate results of post-test with Bonferroni’s correction applied; (E) Shows survival of 
naïve and immunized mice (n = 4–5 mice per group). Statistical significance was determined 
by performing Kaplan-Meier analysis in conjunction with a log rank test. The p values 
indicate significant differences between survival of the indicated groups and the naïve group. 
3. Discussion 
It was reported that LF and EF result in lethality in mice via the cardiac and hepatic systems 
respectively [10]. This presents the important question of how cellular intoxication is affected following 
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vaccination with PA. It is well recognized that immunization with PA leads to anthrax toxin-neutralizing 
PA-specific IgG. It is also appreciated that PA-specific IgG can bind the protein at different sites, 
affecting interaction with the CMG-2 and TEM-8 host receptors, can affect PA polymerization to form 
the heptameric pore, and can affect the interaction with LF and/or EF [22–24]. Some IgG could also be 
deleterious, facilitating transport of LF and/or EF into target cells, thus worsening intoxication. It still 
remains unclear which IgG sub-classes confer protection. Casadevall and colleagues demonstrated that 
a monoclonal IgG2a Ab directed against PA conferred better in vivo protection than the same clone 
engineered as an IgG1 mAb [25]. Through the use of IL-4−/− and IFN−/− mice lacking the capacity to 
produce IgG1 or IgG2c (IgG2a equivalent in B6 mice), we observed that polyclonal IgG1 was a major 
protective IgG sub-class [21]. IgG Fc receptors (FcγR) contribute to protection [25], and different FcγR 
may do so differentially although a rank order of importance of each receptor in vivo has not  
been established. 
Despite the advances in understanding how Ab interacts with toxin and the effector arm of the 
immune system, the effects of PA-specific IgG on organ-specific intoxication remain less-well explored. 
In one study, LT-challenged canines showed improved survival and cardiac function when receiving 
hemodynamic support in combination with anti-PA mAb therapy [26]. Herein we report the surprising 
observation that immunization with PA, while protective against LT-induced lethality, limited 
cardiotoxicity but not hepatotoxicity. This was evidenced as immunized mice having undetectable serum 
cTN1 concentrations but elevated serum ALT and AST following LT challenge. In contrast,  
non-immunized controls had elevated cTn1, ALT and AST. The results therefore suggest that circulating 
PA-specific Ab has a selective ability to protect different organs from intoxication.  
Although IgG titers and survival were improved by inclusion of adjuvants in the vaccine, they did not 
lead to inhibition of the ALT and AST elevation following challenge with LT. This included Alum 
adjuvant which is used in the AVA vaccine as well as experimental adjuvants including CD1d-binding 
ligand αGC and TLR9-activating CpG DNA. Since immunization with PA alone efficiently blocked 
cardiotoxicity, it was not surprising that inclusion of adjuvants did not further enhance this effect. 
However, as mentioned, adjuvants did boost survival following challenge with a high dose of LT. 
Although the IgG1 titers were modestly (2–4 fold) enhanced by Alum or α-GC, there was a profound 
difference in survival. This suggests that a threshold of high affinity Ab that binds neutralizing epitopes 
must be attained to permit survival. Our study involved the administration of relatively high amounts of 
LT, but was consistent with other challenge studies where typically 3–4 fold more protein is administered 
to the relatively LT-resistant B6 mice than the more susceptible BALB/c or A/J mice [7,20,27–29]. The 
amount of LT administered in previous challenge studies appears to exceed that which has previously 
been detected in the bloodstream of infected guinea pigs and mice [30,31]. However, Tang, and 
colleagues demonstrated that most (>95%) of LT administered to mice by the intravenous route cannot 
be detected in the sera as little as two hours after treatment and is only 2–3 fold higher than that detected 
after challenge with 107 live Ames 35 strain spores [31]. It therefore appears that inactivation and 
clearance of LT delivered as an intravenous bolus (especially in immunized animals) is likely to remove 
or neutralize much of the LT that was originally administered. This notion is supported by Tang and 
colleagues, who demonstrated detection of higher amounts of an un-cleavable form of PA after using it 
for challenge (PA-U7) [31]. Therefore, the measured concentrations of PA in the serum following natural 
infection cannot be assumed to be discordant with the amount of protein used for LT challenge experiments. 
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Our data raise the question of why would circulating PA-specific IgG protect the heart from 
intoxication but not protect the liver. LT and ET cause lethality via expression of the high affinity PA 
receptor CMG-2 on cardiac myocytes and hepatocytes respectively [10]. Differential expression of 
CMG-2 could therefore be a factor in the remaining hepatotoxicity. It is also possible that because 
circulating IgG immune complexes are cleared by the liver in an Fc receptor-dependent manner [32,33], 
a good IgG titer that protects the heart also directs some IgG/LT complexes to the liver that is able to 
still bind CMG-2 and intoxicate hepatocytes. 
Since LT lethality does not appear to be mediated by the liver [10], one could assume that the 
remaining hepatotoxicity does not present a problem or limitation of the PA-based vaccine. However, 
residual hepatotoxicity mediated by ET following natural infection could lead to morbidity even in  
PA-vaccinated individuals, or perhaps predispose to later hepatic disease. A system-wide assessment of 
organ-specific protection following toxin challenge would be a worthwhile endeavor and perhaps prompt 
consideration of complementary vaccine strategies that offer a more comprehensive protection of  
the host. 
4. Materials and Methods 
4.1. Reagents 
BL21 competent cells were purchased from Invitrogen (Carlsbad, CA). The pET15b plasmids 
encoding PA and LF respectively were a gift from Dr. J. Collier (Harvard Medical School) and have 
been described previously [1]. HRP-conjugated anti-IgG1, -IgG2b and -IgG2c were purchased from 
Southern Biotechnology (Birmingham, AL, USA). The αGC ligand was purchased from Axorra Inc. 
(San Diego, CA, USA). Imject Alum was purchased from Pierce Biotechnology (Rockford, IL, USA). 
CpG DNA (ODN1826) was purchased from Invivogen (San Diego, CA, USA). Kits for measurement 
of Aspartyl aminotransferase (AST) and Alanine aminotransferase (ALT) were purchased from Bio 
Scientific Corp. (Austin, TX, USA). The cardiac Troponin 1 (cTn1) kit was purchased from Life 
Diagnostics Inc. (West Chester, PA, USA). 
4.2. Toxin Expression and Purification 
Histidine-tagged PA and LF were expressed separately in competent BL21 Escherichia coli 
(Invitrogen, Carlsbad, CA, USA) transformed with the pET15b-rPA, pET15b-rLF and pET15brLFH690C 
plasmids respectively. PA and LF were then purified from bacterial lysates using standard methods also 
described previously [34]. In brief, PA and LF purification was achieved using a 5 mL HisTrap affinity 
column (GE Life Sciences, Piscataway, NJ, USA). LPS contamination was removed by from purified 
PA and LF using an EndoTrap Red LPS-binding affinity column (Lonza, Walkersville, MD, USA). 
4.3. Mice  
Female C57Bl/6 mice were purchased from the National Cancer Institute (Bethesda, MD, USA). 
Experiments were performed on mice aged 6–10 weeks. 
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4.4. Ethics Statement 
All animal procedures reported herein were approved by the University of Oklahoma Health Sciences 
Center Institutional Animal Care and Use Committee (IACUC) and work performed under protocol  
(11-120-HI) in accordance with guidelines established by the NIH Office of Laboratory Animal Welfare. 
4.5. Retro-Orbital Eye Bleed and Serum Collection 
Mice were anesthetized using a vaporized 4% isofluorane/96% oxygen mixture and 100 μL blood 
collected by retro-orbital bleed with heparinized micro-capillary tubes (Fisher Scientific, Hampton, NH, 
USA). Samples were transferred immediately to polypropylene micro-centrifuge tubes. Blood samples 
were incubated for 30 min at room temperature then allowed to clot overnight at 4 °C, before 
centrifugation at 13,000 g for 15 min at 4 °C. Sera were withdrawn with a pipette and stored in aliquots 
at −20 °C. 
4.6. Immunizations and Experimental Schedule  
A single subcutaneous (s.c.) immunization was administered over both flanks on day 0 immediately 
following collection of pre-bleed sera. Unless indicated otherwise, immunizations consisted of 8 μg PA 
in 200 μL sterile-endotoxin-free PBS or PA mixed with 4 μg of αGC, 5 µg of CpG DNA, or adsorbed 
to 100 µL of Imject Alum. Mice were then bled at day 28 post-immunization and sera obtained.  
On day 28, mice were bled and then boosted s.c. with 5 μg of PA in PBS and bled on day 45 and day 90. 
At the end of the experimental period, mice were either challenged with toxin or euthanized in order to 
obtain liver tissue. 
4.7. In Vivo Toxin Challenge 
The LF and PA subunits were mixed at a 1:1 molar ratio in PBS. An amount of lethal toxin equivalent 
to 200 μg PA and in a 100 μL volume was then administered by the i.v. para-orbital route to mice. 
Procedure associated-deaths precluded the use of anesthesia for in vivo challenge assays. This protocol 
was approved by the IACUC and a qualified veterinarian (S.K.J.) administered the toxin. Where 
indicated, after 24 h a second dose equivalent to 100 μg PA was administered. When PA, LF, or mutant 
LF were administered separately, 200 µg of protein was used. The mice were then monitored daily for 
the duration of the experiment and time to death or moribund-based euthanasia recorded. 
4.8. ELISA for Serum Ig  
Immulon 4 ELISA–plates (Dynex Technologies Inc. Chantilly, VA, USA), were coated with PA at 
10 μg/mL in binding buffer (0.1 M Na2HPO4, pH 9.0), overnight at 4°C before washing plates and 
blocking for 2 h at room temperature with 1.0 % w/v BSA in PBS/0.05% v/v Tween 20. Sera were 
diluted 100, 1000, or 10,000 fold in PBS/0.05% v/v Tween as appropriate and then subjected to 2-fold 
serial dilutions. Dilutes sera was then added to PA-coated, pre-blocked plates. Plates were incubated 
overnight at 4 °C with diluted sera, before washing 4 times in PBS/0.05% v/v Tween 20. Plates were 
incubated for 1 h at room temperature with HRP-conjugated anti-mouse IgG1, IgG2b or IgG2c at a final 
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concentration of 0.2 μg/mL. Plates were washed and developed for 5 min at room temperature using  
90 μL of ABTS substrate per well (KPL, Gaithersburg, MD, USA). Reactions were stopped by addition 
of 110 μL of a 10% w/v SDS solution. Plates were analyzed using a Dynex MRX Revelation plate reader. 
Endpoint titers were determined as O.D. <0.01 at 405 nm (equivalent to O.D. of 1/200 dilution of  
pre-bleed sera). Individual Ab titers were plotted as geometric means using GraphPad Prism software. 
A non-parametric Mann-Whitney U test was used to assess experiments with two experimental groups. 
Multiple experimental groups were assessed by one-way ANOVA with Dunn’s post-test. 
4.9. AST, ALT, and cTn1 Measurement  
Serum concentrations of AST, ALT and cTn1 were measured using commercial assay kits according 
to manufacturers’ instructions. 
4.10. Histological Analysis of Liver 
Livers were collected from terminally-moribund animals after euthanasia and from groups treated 
with LT or PBS. Livers were preserved in 10% neutral-buffered formalin for 24 h then dehydrated and 
embedded in paraffin. Tissues were then sectioned and stained with hematoxylin and eosin and subjected 
to microscopic analysis. Scoring for LT-associated pathology was performed in a blinded fashion. 
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